RecruitingEarly Phase 1NCT05145361

Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)

Studying Neuromyelitis Optica

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Principal Investigator
Fu-Dong Shi, MD,PhD
Tianjin Medical University General Hospital
Intervention
B001 injection(drug)
Enrollment
45 enrolled
Eligibility
18 years · All sexes
Timeline
20222025

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05145361 on ClinicalTrials.gov

Other trials for Neuromyelitis Optica

Additional recruiting or active studies for the same condition.

See all trials for Neuromyelitis Optica

← Back to all trials